Tepotinib latest price in 2024

Tepotinib (Tepotinib), trade name: Tepmetko, is an oral small molecule tyrosine kinase inhibitor (TKI) that specifically targets the mesenchymal epidermal transforming factor receptor (MET) for targeted therapy. MET is a receptor tyrosine kinase that plays a key role in various cancers. Its abnormal activity is closely related to the occurrence, development and metastasis of tumors. Tepotinib inhibits the growth and spread of tumor cells by inhibiting the activation of MET and blocking its downstream signaling pathways.

Tepotinib is currently on the market in China, but it is not included in medical insurance. The price for patients to purchase it domestically is relatively high, about more than 30,000 yuan. For specific results, please consult the local hospital pharmacy. The cheaper ones abroad are mainly Laotian generic drugs, which cost around more than 9,000 yuan and have basically the same ingredients as domestic original drugs.

Tepotinib is mainly used to treat metastatic non-small cell lung cancer (NSCLC) carrying METexon14 skipping mutations. This mutation leads to increased stability of the MET protein, thereby promoting the growth and survival of cancer cells. Clinical studies have shown that tepotinib has a significant effect on patients with NSCLC skipping mutations in MET exon 14 and can significantly delay disease progression and improve the overall survival rate of patients.

Leading clinical trials of tepotinib include the VISION study, a multicenter, single-arm, open-label clinical trial evaluating the efficacy and safety of tepotinib in patients with advanced NSCLC harboring METexon 14 skipping mutations. Research results show that tepotinib has a high objective response rate (ORR) and durable therapeutic effect in such patients, and its side effects are relatively controllable. Common adverse reactions include edema, nausea, diarrhea, fatigue and abnormal liver function.

The application of tepotinib marks a milestoneAn important development in MET targeted therapy provides a new treatment option for lung cancer patients carrying specific gene mutations. Especially in cases where traditional treatments are ineffective or are resistant to other TKIs, tepotinib shows good therapeutic prospects. However, although tepotinib has shown significant efficacy in specific patient groups, its long-term efficacy and safety still require further study and observation.